Affinity markers for human serum albumin
View Patent ↗Methods and compositions are provided for identifying compounds having affinity or complementarity to a target molecule. Compounds according to the invention may be described by the formula E-C a —R—C b -A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C a and C b are connector groups between E and R and between R and A, respectively, and A is an affinity group comprising the sequence F- 1 -Y-E-E. Compounds according to the invention may be used for labeling the target molecule, particularly where the target molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long-lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding protein or as an enzyme inhibitor.
1. An affinity group comprising the sequence Phe-(D-Leu)-Tyr-Glu-Glu.
2. A compound comprising the affinity group of claim 1 wherein the compound has the formula E-C a —R—C b -A, wherein E is a therapeutic or diagnostic agent, R is a reactive group, C b and C a are optional first and second connecting groups, respectively, and A is the affinity group.
3. A compound according to claim 2 , wherein the reactive group comprises a functional group selected from the group consisting of carboxy, phosphoryl, alkyl esters, thioesters, phosphoesters, ortho esters, imidates, mixed anhydrides, amides, thioamines and disulphides.
4. A compound according to claim 3 , wherein C b is absent and the reactive group is bonded directly to the F residue in the affinity group.
5. A compound according to claim 4 , wherein the reactive group is bonded to the F residue by an amide linkage.
6. A compound according to claim 2 , wherein the reactive group has the formula —X—R 1 —C(O)—, wherein R 1 comprises a substituted or unsubstituted aromatic group and X is selected from the group consisting of S, O and N.
7. A compound according to claim 6 , wherein X is bonded directly to an aromatic carbon atom in R 1 .
8. A compound according to claim 6 , wherein R 1 is unsubstituted phenyl.
9. A compound according to claim 8 , wherein —X— and —C(O)— are bonded to the phenyl in a para configuration.
10. A compound according to claim 6 , wherein R 1 is phenyl substituted with one or more groups selected from the group consisting of a halogen, NO 2 , SO 2 NH 2 , SO 2 NHF, CF 3 , CCl 3 , CBr 3 , C≡N, SO 3 H, CO 2 H, CHO, OH, NHCOCH 3 , OCH 3 , CH 3 , and CH 2 CH 3 .
11. A compound according to claim 6 , wherein said Phe of said affinity group comprises an amino group, and said reactive group comprises a carbonyl group, wherein a covalent bond is present between said amino group and said carbonyl group.
12. A compound according to claim 3 , wherein C b is present.
13. A compound according to claim 10 , wherein C b is bonded to the reactive group via an ester, thioester, amide, sulfonate ester or sulfonamide linkage.
14. A compound according to claim 12 , wherein C b is bonded to the affinity group via an ester, thioester, amide, sulfonamide, urea, thiourea or carbamate linkage.
15. A compound according to claim 12 , wherein C b comprises a backbone chain of between 1 and 25 atoms.
16. A compound according to claim 15 , wherein C b comprises a backbone chain of between 2 and 16 carbon atoms.
17. A compound according to claim 12 , wherein C b comprises an unsaturated carbon atom backbone chain of between 1 and 25 atoms.
18. A compound according to claim 2 , wherein C a is present.
19. A compound according to claim 18 , wherein C a is bonded to E by an ester, thioester, amide, sulfonate ester or sulfonamide linkage.
20. A compound according to claim 18 , wherein C a is bonded to the reactive group by an ester, thioester, amide or sulfonate ester linkage.
21. A compound according to claim 18 , wherein C a comprises a backbone chain of between 1 and 25 atoms.
22. A compound according to claim 21 , wherein C a comprises a backbone chain of between 2 and 16 carbon atoms.
23. A compound according to claim 18 , wherein C a comprises an unsaturated carbon atom backbone chain of between 1 and 25 atoms.
24. A compound according to claim 18 , wherein the diagnostic agent comprises biotin.
25. A compound according to claim 24 , wherein biotin is bonded directly to the reactive group by an ester, thioester or amide linkage.
26. A compound according to claim 24 , wherein the reactive group has the formula —X-Ph-C(O)—, and wherein X is oxygen, sulfur or nitrogen.
27. A compound according to claim 26 , wherein the —X— and —C(O)— on the phenyl group are bonded in a para configuration.
28. A compound according to claim 25 , wherein C a is present.
29. A compound according to claim 28 , wherein C a is bonded to the biotin group by an amide linkage.
30. A compound according to claim 28 , wherein C a is —NH—(CH 2 ) n ——C(O)—, wherein n is an integer between 1 and 25.
31. A compound according to claim 30 , wherein C a is —NH—(CH 2 ) 5 —C(O)—.
32. A compound according to claim 30 , wherein C a is —NH—CH 2 —C(O)—.
33. The compound of claim 2 , wherein said compound is selected from the group consisting of biotin-S-Ph-C(O)Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 , biotin-OPh-C(O)Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 , LC-biotin-S-Ph-C(O)Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 , biotin-Gly-OPh-C(O)Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 , fluorescein-Gly-OPh-Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 , LC-biotin-OPh-C(O)Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 , and fluorescein-thiourea-AEA 3 -Gly-OPh-C(O)Phe-(D-Leu)-Tyr-Glu-Glu-NH 2 .